Bioelectronic medicine maker Tivic Health's Q3 net loss widens

Reuters
2025/11/15
Bioelectronic medicine maker <a href="https://laohu8.com/S/TIVC">Tivic Health</a>'s Q3 net loss widens

Overview

  • Tivic Health Q3 revenue rises to $146,000, final quarter for direct ClearUP sales

  • Net loss widens to $2.6 mln in Q3, impacted by consumer business wind down

Outlook

  • Company did not provide specific financial guidance for future quarters or years

Result Drivers

  • MILITARY INTEREST - Tivic advanced discussions on deploying Entolimod as a military countermeasure at MHSRS

  • Operating expenses totaled $2.3 million, compared with $1.5 million for the same period in 2024.

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$146,000

Q3 Net Income

-$2.60 mln

Q3 Basic EPS

-$1.97

Q3 Gross Profit

-$145,000

Q3 Operating Expenses

$2.34 mln

Q3 Operating Income

-$2.48 mln

Press Release: ID:nACSKJPQDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10